Idiopatiske inflammatoriske myopatier (IIM)

Forfattere

  • Helena Andersson

DOI:

https://doi.org/10.5324/nje.v18i1.72

Sammendrag

Inflammatoriske muskelsykdommer er en heterogen gruppe av sykdommer der man i dag inkluderer polymyositt (PM), dermatomyositt (DM) og inklusjonslegememyositt (IBM). IBM er den hyppigste forekommende hos personer > 50 år med en prevalens på 39,5/million i denne aldersgruppen. Insidens av PM/DM er beregnet til 2-10/million med en prevalens på 11/100.000. Spesielt PM og DM kan ha andre organmanifestasjoner der eksempelvis interstitiell lungesykdom kan gi alvorlig sykdom med økt morbiditet og mortalitet. Økt cancer-risiko er påvist spesielt hos DM, evt PM men ikke hos IBM. I den senere tid har man identifisert nye kliniske fenotyper av PM og DM, spesielt gjennom myosittspesifikke antistoff. Noen av disse kan brukes som markører for prognose og sykdomsaktivitet. Det er ønskelig med enhetlig internasjonal
klassifikasjon som også omfatter myosittspesifikke antistoff til å utføre nye epidemiologiske/kliniske studier og dermed øke kunnskapen om disse sykdommene

Idiopathic inflammatory myopathies comprehense a group of heterogenous diseases including polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM). The most common disease in persons > 50 years is IBM. The prevalence of IBM in this particular age-group is 39.5/million. The incidence of PM/DM is 2-10/ million, and the prevalence 11/100,000. Other organ manifestations could be present in IIM, specially in PM and DM. One example is interstitial lung disease which often lead to increased morbidity and mortality. In particular DM has an increased risk of cancer, probably also PM, but not IBM. In recent years identification of new clinical phenotypes of PM/DM has been made, mostly by myositisspecific antibodies. Some of these can be used as markers of prognosis and disease activity. For future
epidemiological and clinical studies, which can increase our knowledge of these diseases, a unified, international classification that also include myositis-specific antibodies is highly warranted.

Downloads

Download data is not yet available.

Nedlastinger

Publisert

2009-10-05

Hvordan referere

Andersson, H. (2009). Idiopatiske inflammatoriske myopatier (IIM). Norsk Epidemiologi, 18(1). https://doi.org/10.5324/nje.v18i1.72

Utgave

Vol 18 Nr 1 (2008): The epidemiology of rheumatic diseases / Revmatiske sykdommers epidemiologi

Seksjon

Articles

Lisens

Norsk Epidemiologi licenses all content of the journal under a Creative Commons Attribution (CC-BY) licence. This means, among other things, that anyone is free to copy and distribute the content, as long as they give proper credit to the author(s) and the journal. For further information, see Creative Commons website for human readable or lawyer readable versions.

Authors who publish with this journal agree to the following terms:

1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).